TY-302 is under clinical development by Tetranov International and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TY-302’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TY-302 overview
TY-302 Is under development for the treatment of solid tumors including HR+/HER2- locally advanced metastatic breast cancer, acute myeloid leukemia, ovarian cancer, melanoma, lung cancer, triple-negative breast cancer, head and neck tumors and prostate cancer. The therapeutic candidates are palbociclib derivatives and act by targeting cyclin-dependent kinase 4 and 6 (CDK4/6). It is administered through oral route.
For a complete picture of TY-302’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.